Themis Medicare Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Themis Medicare Share Price

101.81-0.83 (-0.81%)

Closed
As On: 18 Jun, 2026, 03:43 PM IST
As On: 18 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	103.57
High	103.57
Low	101.23
Prev Close	102.64
Volume	44,016
VWAP(₹)	102.16

Key Metrics

PE Ratio(x)	819.71
EPS - TTM(₹)	0.12
MCap(₹ Cr.)	937.67
MCap Rank	90
PB Ratio(x)	2.37
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	148.00
52W Low(₹)	64.95
MCap/Sales	1.77
Beta(1 Month)	1.23
BV/Share(₹)	43.28

Themis Medicare share price insights

Passing Profits to Shareholders
Company has consistently declining ROE in last 5 years. Majority of profits last year were disbursed as dividends to shareholders. (Source: Consolidated Financials)
Topline Contraction
Sales de-grew by 14.28%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 3.12% of its operating revenues towards interest expenses and 27.33% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Themis Medicare Share Price Update
Themis Medicare Ltd. share price moved down by -0.81% from its previous close of Rs 102.64. Themis Medicare Ltd. stock last traded price is 101.81
Share Price Value
Today/Current/Last 101.81101.60
Previous Day 102.64103.45

Found Insights useful?

Themis Medicare Share Price Returns

1 Day	-0.81%
1 Month	3.74%
3 Months	35.28%
1 Year	-21.47%
3 Years	-28.82%
5 Years	42.63%

Themis Medicare Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Themis Medicare Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	91.42	81.23	98.75	73.25	94.83
Total Income Growth (%)	12.54	-17.74	34.81	-22.75	-19.74
Total Expenses	83.79	83.66	110.21	80.02	87.82
Total Expenses Growth (%)	0.16	-24.10	37.74	-8.88	-14.18
EBIT	7.62	-2.43	-11.46	-6.76	7.01
EBIT Growth (%)	-	-	-	-196.48	-55.67
Profit after Tax (PAT)	10.09	-3.62	-14.22	-9.66	0.52
PAT Growth (%)	-	-	-	-1,961.04	-96.37
EBIT Margin (%)	8.34	-2.99	-11.60	-9.23	7.39
Net Profit Margin (%)	11.04	-4.45	-14.40	-13.19	0.55
Basic EPS (₹)	1.10	-0.39	-1.54	-1.05	0.06

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	91.42	81.23	98.75	73.25	94.83
Total Income Growth (%)	12.54	-17.74	34.81	-22.75	-5.51
Total Expenses	83.79	83.66	111.50	80.01	87.82
Total Expenses Growth (%)	0.16	-24.97	39.36	-8.89	5.01
EBIT	7.62	-2.43	-12.75	-6.76	7.01
EBIT Growth (%)	-	-	-	-196.38	-58.10
Profit after Tax (PAT)	4.58	-5.36	-15.37	-7.74	3.08
PAT Growth (%)	-	-	-	-351.36	-68.78
EBIT Margin (%)	8.34	-2.99	-12.91	-9.22	7.39
Net Profit Margin (%)	5.01	-6.59	-15.57	-10.57	3.25
Basic EPS (₹)	0.50	-0.58	-1.67	-0.84	0.33

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	410.18	386.52	365.83	401.16	234.29
Total Revenue Growth (%)	6.12	5.66	-8.81	71.22	14.26
Total Expenses	376.43	351.88	306.93	317.23	202.44
Total Expenses Growth (%)	6.98	14.64	-3.25	56.71	8.21
Profit after Tax (PAT)	29.83	43.52	56.90	72.88	35.70
PAT Growth (%)	-31.46	-23.51	-21.93	104.13	44.07
Operating Profit Margin (%)	10.79	11.52	19.32	23.49	19.32
Net Profit Margin (%)	7.35	11.40	16.05	18.46	15.47
Basic EPS (₹)	3.24	4.73	61.83	79.22	38.86

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	410.18	386.52	365.83	401.16	234.29
Total Revenue Growth (%)	6.12	5.66	-8.81	71.22	14.26
Total Expenses	376.42	351.85	306.92	317.22	202.04
Total Expenses Growth (%)	6.98	14.64	-3.25	57.00	8.01
Profit after Tax (PAT)	23.92	24.75	43.29	61.56	26.62
PAT Growth (%)	-3.34	-42.84	-29.67	131.24	67.30
Operating Profit Margin (%)	10.80	11.53	19.32	23.49	19.49
Net Profit Margin (%)	5.89	6.48	12.21	15.59	11.54
Basic EPS (₹)	2.60	2.69	47.05	66.91	28.97

All figures in Rs Cr, unless mentioned otherwise

Insights

Topline Contraction
Sales de-grew by 14.28%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 3.12% of its operating revenues towards interest expenses and 27.33% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	588.03	566.42	513.96	427.78	371.14
Total Assets Growth (%)	3.82	10.21	20.14	15.26	6.07
Total Liabilities	185.43	188.75	174.51	140.29	152.63
Total Liabilities Growth (%)	-1.76	8.16	24.39	-8.09	-8.54
Total Equity	402.60	377.67	339.44	287.49	218.51
Total Equity Growth (%)	6.60	11.26	18.07	31.57	19.39
Current Ratio (x)	1.95	1.90	1.90	1.96	1.45
Total Debt to Equity (x)	0.21	0.25	0.27	0.27	0.36
Contingent Liabilities	26.81	18.76	18.75	13.75	16.56

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	505.65	489.97	456.29	383.74	338.40
Total Assets Growth (%)	3.20	7.38	18.91	13.40	3.75
Total Liabilities	185.37	188.69	174.46	140.26	152.60
Total Liabilities Growth (%)	-1.76	8.16	24.38	-8.09	-8.55
Total Equity	320.29	301.28	281.83	243.48	185.80
Total Equity Growth (%)	6.31	6.90	15.75	31.04	16.63
Current Ratio (x)	1.96	1.91	1.91	1.97	1.46
Total Debt to Equity (x)	0.26	0.32	0.33	0.32	0.43
Contingent Liabilities	27.12	18.76	18.75	9.39	16.56

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	34.71	22.09	16.09	34.39	56.98
Net Cash used in Investing Activities	-12.17	-15.95	-23.96	-15.59	-15.65
Net Cash flow from Financing Activities	-25.90	-8.77	0.14	-17.55	-25.65
Net Cash Flow	-3.36	-2.62	-7.73	1.26	15.68
Closing Cash & Cash Equivalent	6.56	9.92	12.55	20.28	19.02
Closing Cash & Cash Equivalent Growth (%)	-33.89	-20.92	-38.13	6.63	469.15
Total Debt/ CFO (x)	2.39	4.34	5.71	2.28	1.39

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	34.71	22.04	16.07	34.39	56.98
Net Cash used in Investing Activities	-12.17	-15.96	-23.96	-15.58	-15.65
Net Cash flow from Financing Activities	-25.90	-8.77	0.14	-17.55	-25.65
Net Cash Flow	-3.36	-2.68	-7.75	1.26	15.68
Closing Cash & Cash Equivalent	6.47	9.83	12.51	20.27	19.00
Closing Cash & Cash Equivalent Growth (%)	-34.21	-21.45	-38.26	6.64	471.04
Total Debt/ CFO (x)	2.39	4.35	5.72	2.28	1.39

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 2.54 cr for investing activities which is an YoY decrease of 79.1%. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	7.41	11.52	16.76	25.35	16.33
Return on Capital Employed (%)	10.13	10.68	18.26	29.12	18.35
Return on Assets (%)	5.07	7.68	11.07	17.03	9.61
Interest Coverage Ratio (x)	5.35	6.00	8.26	11.64	3.51
Asset Turnover Ratio (x)	0.70	0.71	0.75	1.05	62.15
Price to Earnings (x)	45.25	46.51	18.87	11.79	7.22
Price to Book (x)	3.35	5.34	3.16	2.99	1.18
EV/EBITDA (x)	26.43	37.19	14.52	8.91	5.87
EBITDA Margin (%)	13.24	14.73	22.28	25.89	23.02

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	7.46	8.21	15.36	25.28	14.32
Return on Capital Employed (%)	12.52	13.12	21.58	33.80	21.39
Return on Assets (%)	4.73	5.05	9.48	16.04	7.86
Interest Coverage Ratio (x)	5.35	6.00	8.26	11.65	3.54
Asset Turnover Ratio (x)	0.81	0.81	0.84	1.09	68.16
Price to Earnings (x)	56.50	81.97	24.81	13.95	9.68
Price to Book (x)	4.21	6.69	3.81	3.53	1.39
EV/EBITDA (x)	26.43	37.17	14.52	8.91	5.83
EBITDA Margin (%)	13.25	14.74	22.28	25.89	23.19

Insights

Passing Profits to Shareholders
Company has consistently declining ROE in last 5 years. Majority of profits last year were disbursed as dividends to shareholders. (Source: Consolidated Financials)

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Themis Medicare	819.71	2.35	0.28	-0.13	0.19	-1.30	-0.16	-3.77	0.12	1.84	0.25	-30.65
Syncom Form	17.19	3.17	18.41	23.76	14.31	29.31	20.90	15.62	0.81	3.18	0.00	0.03
Lincoln Pharma	13.87	1.61	11.60	14.96	9.87	9.66	17.38	13.09	43.88	5.25	0.01	0.04
Bajaj Healthcare	67.70	2.00	2.95	14.28	1.70	-2.86	13.81	2.58	4.98	1.92	0.44	4.02
Fermenta Biotech	12.93	2.34	17.86	22.88	11.20	15.11	19.13	13.37	24.70	1.86	0.27	1.17
Add More

Annual Ratios (%)

Choose from Peers

Wanbury Ltd
Kopran Ltd
Anuh Pharma
Kilitch Drug
Praveg Comm

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 6,18,03,990 67.11 % 0.00
Pledge 15,00,000 2.43 % 0.00
FII 98,529 0.11 % 0.06
DII 1,192 0.00 % 0.00
MF 1,192 0.00 % 0.00
Others 3,01,96,409 32.78 % -0.06
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 67.11 67.11 67.15 67.15
Pledge 2.43 2.43 2.43 2.43
FII 0.11 0.05 0.06 0.09
DII 0.00 0.00 0.00 0.00
Mutual Funds 0.00 0.00 0.00 0.00
Others 32.78 32.84 32.78 32.75

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.02%
  % of AUM
- -9.36
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.00
  Amount Invested (in Cr.)
- 0.02%
  % of AUM
- 7.02
  % Change (MoM basis)

View all Mutual Fund Schemes

Themis Medicare Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results & Final Dividend
May 26, 2026
General Meeting
-
Mar 06, 2026
Board Meeting
Quarterly Results & issue of Warrants
Feb 11, 2026

Announced on	Meeting on
May 26, 2026	May 28, 2026
Audited Results & Final Dividend
Feb 11, 2026	Feb 13, 2026
Quarterly Results & issue of Warrants
Nov 04, 2025	Nov 13, 2025
Quarterly Results
Jul 28, 2025	Aug 01, 2025
Quarterly Results
May 15, 2025	May 20, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 20, 2025 Sep 04, 2025 50%
May 14, 2024 Jul 12, 2024 50%
May 15, 2023 Sep 01, 2023 50%
May 23, 2022 Sep 08, 2022 50%
May 27, 2021 Sep 08, 2021 43%
Bonus
No Data Available
Splits
Announced on Ex-Date
May 13, 2023 Oct 10, 2023
Split: Old FV10.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Mar 06, 2026 Mar 31, 2026
-
Aug 19, 2025 Sep 12, 2025
-
Feb 20, 2025 Mar 25, 2025
-
May 15, 2024 Jul 22, 2024
Book closure from Jul 15, 2024 to Jul 22, 2024
Mar 11, 2024 Apr 09, 2024
-

About Themis Medicare

Themis Medicare Ltd., incorporated in the year 1969, is a Small Cap company (having a market cap of Rs 937.67 Crore) operating in Pharmaceuticals sector.

Themis Medicare Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 80.20 Crore, down 12.27 % from last quarter Total Income of Rs 91.42 Crore and up 9.48 % from last year same quarter Total Income of Rs 73.25 Crore. Company has reported net profit after tax of Rs 1.96 Crore in latest quarter.

The company’s top management includes Dr.Dinesh S Patel, Dr.Sachin D Patel, Dr.Adam Demeter, Mr.Rajneesh K Anand, Mr.Bhaskar V Iyer, Ms.Manjul Sandhu, Ms.Neha Thakore, Mr.Nikunt K Raval, Mr.Shishir V Dalal, Mrs.Reena S Patel, Mr.Tushar J Dalal, Mr.Pradeep M Chandan. Company has Krishaan & Co. as its auditors. As on 31-03-2026, the company has a total of 9.21 Crore shares outstanding.

Themis Medicare Share Price Today is Rs. 101.81. On previous day, the Themis Medicare Share Price (NSE) closed at Rs. 102.64, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 67.11% of the stake in Themis Medicare shares, out of which 2.43% was pledged. On the same date, foreign institutional investors' (FII) holdings of Themis Medicare stocks was 0.11% as compared to 0.05% in Dec 2025 with increase of 0.06%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Themis Medicare shares 0.0% was held by mutual funds. The rest including public held is 32.78%. Themis Medicare stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Themis Medicare Dividend: Ever since 1969, Themis Medicare dividends has been paid out around 18 times. As on 18 Jun, 2026, 03:43 PM IST, The overall dividend yield for Themis Medicare stands at 0.0%. The last dividend paid was on September 4, 2025 (Rs. 0.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 0.12.

Themis Medicare Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 80.2 Cr. of sales and 12.27% of quarterly net loss, there have been multiple ups and downs in the Themis Medicare stock prices in the past few weeks. For example, Themis Medicare stock price on 11th of June 2026 was around Rs. 100.31. Themis Medicare share price now stands at an average of Rs. 101.81. Judging by last week's performance, stock is in up trend.

Themis Medicare has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Themis Medicare share.

Historical Prices and Performance:
Themis Medicare, incorporated in 1969 is a Small Cap company (with a market cap of Rs. 937.67) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Themis Medicare stock was 0.28%, 7.41%, 11.52%, 16.76% and 25.35% respectively.
The Themis Medicare share gave a 3 year return of -28.79% as compared to Nifty 50 which gave a return of 28.38%.
Themis Medicare announced 50.0% final dividend on September 4, 2025.

Key Metrics:
PE Ratio of Themis Medicare is 826.4
Prices/Sales Ratio of Themis Medicare is 1.77
Price/Book Ratio of Themis Medicare is 2.37

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Themis Medicare, major competitors and peers include Syncom Form, Lincoln Pharma, Bajaj Healthcare and Fermenta Biotech. As of Dec 2025, the dividend yield of Themis Medicare stands at 0.0% while Syncom Form, Lincoln Pharma, Bajaj Healthcare and Fermenta Biotech stand at 0.0%, 0.0%, 0.47% and 1.18% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 826.4 and 2.37 respectively.

Leadership of Themis Medicare :
Pradeep M Chandan is Co. Secretary & Compl. Officer
Tushar J Dalal is Chief Financial Officer
Dinesh S Patel is Chairman & Executive Director
Sachin D Patel is Managing Director & CEO
Rajneesh K Anand is Non Executive Director
Adam Demeter is Non Executive Director
Manjul Sandhu is Independent Director
Bhaskar V Iyer is Independent Director
Nikunt K Raval is Independent Director
Neha Thakore is Independent Director
Shishir V Dalal is Independent Director
Reena S Patel is Alternate Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE MidSmallCap

Address

Plot No.69-A,GIDC Industrial Estate,Vapi,Valsad District, Gujarat - 396195

Contact

cfoassist@themismedicare.com

http://www.themismedicare.com

Executive Leadership

DS

Dinesh S Patel

Chairman & Executive Director

SD

Sachin D Patel

Managing Director & CEO

AD

Adam Demeter

Non Executive Director

RK

Rajneesh K Anand

Non Executive Director

Show More

Auditors

Krishaan & Co.

R P Sardar & Co.

FAQs about Themis Medicare share

1. What's Themis Medicare share price today and what are Themis Medicare share returns ?
Themis Medicare share price is Rs 101.81 as on 18 Jun, 2026, 03:43 PM IST. Themis Medicare share price is down by 0.81% based on previous share price of Rs 102.64. Themis Medicare share price trend:
- Last 12 Months: Themis Medicare share price moved down 21.47%
- Last 3 Years: Themis Medicare Share price moved down by 28.82%
2. What's the market capitalization of Themis Medicare?
Market Capitalization of Themis Medicare stock is Rs 937.67 Cr.
3. What is the PE & PB ratio of Themis Medicare?
The PE ratio of Themis Medicare stands at 819.71, while the PB ratio is 2.35.
4. What are the returns for Themis Medicare share?
Return Performance of Themis Medicare Shares:
- 1 Week: Themis Medicare share price moved down by 2.10%
5. What is 52 week high/low of Themis Medicare share price?
Themis Medicare share price saw a 52 week high of Rs 148.00 and 52 week low of Rs 64.95.

Top Gainers

As on 03:59 PM | 18 Jun 2026

789.90

111.40 (16.42%)

1,186.40

143.16 (13.73%)

163.00

16.35 (11.15%)

271.95

23.03 (9.26%)

New India Assurance

178.67

13.21 (7.99%)

Top Losers

As on 03:59 PM | 18 Jun 2026

82.31

-7.76 (-8.62%)

84.62

-5.74 (-6.36%)

1,812.40

-102.70 (-5.37%)

535.00

-23.65 (-4.24%)

1,119.40

-45.70 (-3.93%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.